Recent News

• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.08.2025 - Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
• 03.07.2025 - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.03.2025 - Cowen Annual Health Care Conference
• 02.28.2025 - Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
• 02.20.2025 - Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
• 02.20.2025 - Instafeeds 19 Feb 2025
• 02.20.2025 - Instafeeds 15 Feb 2025
• 02.20.2025 - Instafeeds 11 Feb 2025
• 02.20.2025 - Instafeeds 08 Feb 2025

Recent Filings

• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 144 Report of proposed sale of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 144 Report of proposed sale of securities